Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer
Edmund C.P. Chedgy(University Hospital Southampton NHS Foundation Trust), Alexander W. Wyatt(University of British Columbia), Kim N.(BC Cancer Agency), Martin Gleave(University of British Columbia), Evan W. Warner(Guardant (United States)), Matti Annala(Tampere University), Kevin Beja(University of British Columbia)
Cited by 16
Related Papers
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
|Cancer Discovery|2018|520
Antisense therapy for cancer
|Nature reviews. Cancer|2005|399